Registration Dossier
Registration Dossier
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 460-110-3 | CAS number: 797751-43-0 WASOX-MMAC2
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Endpoint summary
Administrative data
Description of key information
Key study: OECD Guideline 429 and GLP. The test substance Wasox-MMAC2 was regarded as a non sensitizer, since the SIs of all examined test substance concentrations were clearly smaller than 3.
Key value for chemical safety assessment
Skin sensitisation
Link to relevant study records
- Endpoint:
- skin sensitisation: in vivo (LLNA)
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- October 12-19, 2004
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Remarks:
- According to OECD Guideline 429, with GLP.
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 429 (Skin Sensitisation: Local Lymph Node Assay)
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- EU Method B.42 (Skin Sensitisation: Local Lymph Node Assay)
- Deviations:
- no
- GLP compliance:
- yes
- Type of study:
- mouse local lymph node assay (LLNA)
- Species:
- mouse
- Strain:
- CBA
- Sex:
- female
- Details on test animals and environmental conditions:
- TEST ANIMALS
- Source: Harlan Winkelman
- Age at study initiation: 8 weeks
- Weight at study initiation: 17.0-19.9 g
- Housing: single caging. Makrolon cages type II
- Diet (e.g. ad libitum): ad libitum
- Water (e.g. ad libitum): ad libitum
- Acclimation period: 5 days
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 21.8 ºC (average)
- Humidity (%): 48.2% (average)
- Photoperiod (hrs dark / hrs light): only artificial light from 6.00 a.m. to 6.00 p. m. - Vehicle:
- acetone/olive oil (4:1 v/v)
- Concentration:
- High dose: 100% test substance (as it is).
Mid dose: 50% (v/v) solution of the test substance in acetone:olive oil.
Low dose: 25% (v/v) solution of the test substance in acetone:olive oil. - No. of animals per dose:
- five female mice/dose level.
- Details on study design:
- RANGE FINDING TESTS:
- Compound solubility: Solubility testing showed that the test substance solves for at least 50% (v/v) in vehicle AOO.
- Irritation: about 24 hours after the last administration of the test substance as it is (100%) little increase in ear thickness was observed.
TREATMENT PREPARATION AND ADMINISTRATION:
Administration was performed epicutaneously to the dorsal surface of both ears, once a day on three consecutive days. The volume administered was 25 µL per ear. - Positive control substance(s):
- hexyl cinnamic aldehyde (CAS No 101-86-0)
- Positive control results:
- Application of 25% HCA in AOO resulted in a positive control result of 42767 dpm (desintegrations per minute) and a SI (Stimulation Index) of 10.2. This result proves the sensitivity of the strain of animals used and the reliability of the experimental technique.
- Key result
- Parameter:
- SI
- Value:
- 1
- Test group / Remarks:
- Negative control
- Key result
- Parameter:
- SI
- Value:
- 1
- Test group / Remarks:
- Low dose
- Key result
- Parameter:
- SI
- Value:
- 0.8
- Test group / Remarks:
- Mid dose
- Key result
- Parameter:
- SI
- Value:
- 0.7
- Test group / Remarks:
- High dose
- Key result
- Parameter:
- SI
- Value:
- 10.2
- Test group / Remarks:
- Positive control
- Parameter:
- other: disintegrations per minute (DPM)
- Remarks on result:
- other: Negative Control: 4197dpm Low Dose: 4217 dpm Mid Dose: 3536 dpm High Dose: 2919 dpm Positive Control: 42767 dpm
- Interpretation of results:
- other: Not classified (CLP Regulation EC no. 1272/2008)
- Conclusions:
- The test substance Wasox-MMAC2 is regarded as a non sensitizer in the "Skin Sensitisation: Local Lymph Node Assay", since the SIs of all examined test substance concentrations were clearly smaller than 3.
- Executive summary:
The "Skin Sensitisation: Local Lymph Node Assay" for the test substance Wasox-MMAC2 was performed in five groups of 5 female CBA mice (According to OECD Guideline 429). The doses tested were 100% of test material (as it is); 50% (v/v) and 25 % (v/v). The vehicle used was acetone:oil (4:1, v/v) (AOO). A positive control (25% solution of hexyl cinnamic aldehyde in AOO) and a negative control (AOO) were included on the test. Both control substances were administrated under identical conditions as the test substance. The Administration was performed epicutaneously to the dorsal surface of both ears, once a day on three consecutive days. The volume administrated was 25 µl per ear. 5 days after the first topical administration, each animal received 20 µlCi3HTdR by intravenous administration. Approximately 5 hour after 3HTdR injection all animals were sacrificed and the 3HTdR incorporation determinate. The application sites were visually checked for local irritations at least once a day. Body weight was recorded on days 1 and 6 after the administration. The test substance is regarded as a not sensitising, since the SIs of all examined test substance concentrations were clearly smaller than 3, and therefore the substance was determined to be not sensitising.
- Endpoint:
- skin sensitisation: in vitro
- Data waiving:
- study scientifically not necessary / other information available
- Justification for data waiving:
- an in vitro skin sensitisation study does not need to be conducted because adequate data from an in vivo skin sensitisation study are available
- Justification for type of information:
- JUSTIFICATION FOR DATA WAIVING
An in vitro study does not need to be conducted since adequate data from an in vivo skin sensitisation study are available.
Referenceopen allclose all
Mortality:
All animals survived till the end of the study.
General observations:
One animal of group C had reduced motoric activities on Day 6. In all other animals no abnormal behaviour or clinical signs were detected during the experiment.
Skin reactions:
No local irritations were observed at the application sites of all animals of all test substance groups and both control groups throughout the whole study.
Body masses:
Body masses and body mass gains of all animals were in the range to be expected from animals of the same strain, sex and age.
Body weight loss was noted in 1/5 animals in group B and C.
Body mass of the animals on Days 1 and 6. Individual body masses (b.m.) and body mass gains in g of all animals. Means, standard deviations (SD) and number of animals per group (n).
Group K (negative control) |
Group A (low dose) |
Group B (mid dose) |
Group C (high dose) |
Group P (positive control) |
|||||||||||||||
Animal no, |
b.m. on day |
b.m. gain |
Animal no, |
b.m. on Day |
b.m. gain |
Animal no, |
b.m. on Day |
b.m. gain |
Animal no, |
b.m. on Day |
b.m. gain |
Animal no, |
b.m, on Day |
b.m. gain |
|||||
1 |
6 |
1 |
6 |
1 |
6 |
1 |
6 |
1 |
6 |
||||||||||
1 |
18.9 |
21,1 |
2.2 |
6 |
17.8 |
19.2 |
1.4 |
11 |
19.8 |
19.4 |
-0.4 |
16 |
19.9 |
20.9 |
1.0 |
21 |
18.3 |
19.0 |
0.7 |
2 |
18.7 |
20.3 |
1.6 |
7 |
17.3 |
19.3 |
2.0 |
12 |
17.8 |
20.0 |
2.2 |
17 |
18.6 |
20.0 |
1.4 |
22 |
19.9 |
21.3 |
1.4 |
3 |
19.4 |
20.0 |
0.6 |
8 |
18.8 |
21.7 |
2.9 |
13 |
17.8 |
20.8 |
3.0 |
18 |
17.6 |
16.9 |
-0.7 |
23 |
17.3 |
18.9 |
1.6 |
4 |
17.8 |
17.8 |
0.0 |
9 |
18.9 |
20.1 |
1.2 |
14 |
18.1 |
20.0 |
1.9 |
19 |
17.3 |
20.7 |
3.4 |
24 |
18.0 |
18.9 |
0.9 |
5 |
19.7 |
21.3 |
1.6 |
10 |
17.0 |
20.9 |
3.9 |
15 |
18.7 |
19.5 |
0.8 |
20 |
18.2 |
19.6 |
1.4 |
25 |
19.3 |
19.8 |
0.5 |
mean |
18.9 |
20.1 |
1.2 |
mean |
18.0 |
20.2 |
2.3 |
mean |
18.4 |
19.9 |
1.5 |
mean |
18.3 |
19.6 |
1.3 |
mean |
18.6 |
19.6 |
1.0 |
SD |
0.7 |
1.4 |
0.9 |
SD |
0.9 |
1.1 |
1.1 |
SD |
0.8 |
0.6 |
1.3 |
SD |
1.0 |
1.6 |
1.5 |
SD |
1.0 |
1.0 |
0.5 |
n |
5 |
5 |
5 |
n |
5 |
5 |
5 |
n |
5 |
5 |
5 |
n |
5 |
5 |
5 |
n |
5 |
5 |
5 |
Simulation index:
Evidence of sensitisation of each challenge concentration:
Results are presented as test/control ratio (Stimulation index), calculated as dpm test group/dpm negative control group, (dpm - disintegrations per minute, corrected by the subtraction of the background).
|
Dpm |
SI |
Group K (negative control) |
4197 |
1 |
Group A (Iow dose) |
4217 |
1.0 |
Group B (mid dose) |
3536 |
0.8 |
Group C (high dose) |
2919 |
0.7 |
Group P (positive control) |
42767 |
10.2 |
The Sis of the test substance groups were between 0.7 and 1.
Application of 25% HCA in AOO resulted in an SI of 10.2. This result proves the sensitivity of the strain of animals used and the reliability of the experimental technique.
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed (not sensitising)
- Additional information:
Key study: The Skin Sensitisation: Local Lymph Node Assay for the test substance Wasox-MMAC2 was performed in five groups of 5 female CBA mice according to OECD Guideline 429 and GLP. The test substance was regarded as a non sensitizer, since the SIs of all examined test substance concentrations were clearly smaller than 3.
Justification for selection of skin sensitisation endpoint:
Only one study available.
Respiratory sensitisation
Endpoint conclusion
- Endpoint conclusion:
- no study available
Justification for classification or non-classification
Based on the available information on skin sensitization, the substance is not classified according to CLP Regulation (EC) no. 1272/2008.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
